Myeloma CAR T-Therapy Among New EMA PRIME Winners

Janssen, Krystal Biotech and Takeda are the latest companies to win a place on the European Medicines Agency’s popular priority medicines scheme for getting drugs for unmet medical needs through the review process faster.

Priority
Three new investigational drugs have won EU priority status • Source: Shutterstock

Janssen’s CAR T-cell therapy, JNJ-68284528, for multiple myeloma is one of three new investigational products that have secured a place on the European Medicines Agency’s priority medicines (PRIME) scheme for getting drugs for unmet medical needs through the review process and to patients faster.

The PRIME designation for Janssen's B-cell maturation antigen (BCMA) CAR T-therapy is expected to help the company keep pace with...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from R&D

More from Pink Sheet